UNI418 compound disrupts cancer DNA repair to restore sensitivity to PARP inhibitors
Researchers have identified a compound that blocks the DNA repair mechanism cancer cells exploit to survive treatment, potentially reversing resistance to PARP inhibitor therapies.
Researchers have identified a small molecule, UNI418, that can disrupt the DNA repair capacity of cancer cells — the very mechanism by which those cells survive treatment with DNA-damaging therapies. The findings, reported via ScienceDaily on 10 June 2026, suggest that cancer cells under treatment pressure compensate by activating repair pathways that counteract the intended damage. UNI418 appears to interfere with this compensatory repair, leaving cancer cells more vulnerable.
Critically, when UNI418 was combined with a PARP inhibitor — a class of agent already established in hereditary cancer treatment, particularly for tumours harbouring BRCA1 or BRCA2 variants — resistant cancer cells regained sensitivity to the drug combination. PARP inhibitors work by blocking an alternative DNA repair route; resistance to these agents is a recognised clinical challenge, and the identification of molecules capable of reinstating responsiveness is an active area of oncology research.
The underlying institution, research team, and journal of publication were not specified in the available source material. Full evaluation of methodology and effect sizes will require access to the primary publication. The findings are reported as preclinical at this stage. No peer-reviewed source was identified in the feed; the summary is based on a press-release-level report.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Cancer cells can sometimes survive treatment by repairing the damage that medicines are designed to cause. Researchers have been studying a compound called UNI418 that may be able to block this repair process, making some cancer cells respond to treatment again even after they had stopped responding.
The research combined UNI418 with an existing type of cancer medicine called a PARP inhibitor, which is already used in some hereditary cancers. In laboratory experiments, this combination appeared to overcome the resistance that certain cancer cells had developed.
This research is at an early stage and has not yet been tested in people. Scientists will need to carry out further studies before this approach could be considered for clinical use.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-06-10Scientists shut down cancer DNA repair to overcome drug resistance